Insights

Rare Disease Focus Capitalize on Travere’s mission and portfolio in rare kidney diseases to position complementary partnerships or co-development opportunities with firms targeting IgA nephropathy and FSGS, leveraging their existing data from SPARTAN, DUPLEX, and PROTECT studies.

FILSPARI Data Momentum Leverage Travere’s ongoing ASN Kidney Week 2026 data presentations on FILSPARI to explore sponsor-agnostic collaborations, expansion of companion diagnostics, or payer strategies that could broaden access and market uptake for sparsentan therapies.

Leadership and Growth With leadership transition underway and a high-profile CEO appointment on the horizon, identify advisory or board-level collaboration, strategic partnerships, or executive-influenced funding rounds that could align with joint development or commercialization ventures.

Strong Revenue Signals Respond to recent revenue growth and profitability indicators by proposing market expansion projects, regional launch support, or value-based pricing collaborations that align with Travere’s financial trajectory and potential appetite for partnerships.

Clinical and Regulatory Expertise Target opportunities that benefit from Travere’s renal disease clinical development leadership, such as access to expert networks, trial site collaborations, and pharmacovigilance partnerships, to accelerate existing programs or co-create new renal indications.

Similar companies to Travere Therapeutics

Travere Therapeutics Tech Stack

Travere Therapeutics uses 8 technology products and services including Alteryx, iCIMS, Snowflake, and more. Explore Travere Therapeutics's tech stack below.

Media & News

Travere Therapeutics's Email Address Formats

Travere Therapeutics uses at least 4 email formats:
Travere Therapeutics Email FormatsExamplePercentage
First.Last@travere.comJohn.Doe@travere.com
91%
First@travere.comJohn@travere.com
5%
Last@travere.comDoe@travere.com
2%
FirstLast@travere.comJohnDoe@travere.com
2%

Frequently Asked Questions

What is Travere Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Travere Therapeutics is a publicly traded company; the company's stock symbol is TVTX.

What is Travere Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Travere Therapeutics's official website is travere.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Travere Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, Travere Therapeutics's annual revenue is estimated to be $250M - $500M.

What is Travere Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
Travere Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Travere Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, Travere Therapeutics has approximately 525 employees across 3 continents, including North America, Europe and Asia. Key team members include Chief Research Officer: B. L., Head Of Finance & Operations Europe / Managing Director / Board Member: C. E. and Senior Vice President, Global Medical Affairs: R. L. C. Explore Travere Therapeutics's employee directory with LeadIQ.

What industry does Travere Therapeutics belong to?

Minus sign iconPlus sign icon
Travere Therapeutics operates in the Biotechnology Research industry.

What technology does Travere Therapeutics use?

Minus sign iconPlus sign icon
Travere Therapeutics's tech stack includes Alteryx, iCIMS, Snowflake, Microsoft 365, ADP Workforce Now, Splunk, Cisco and Coupa.

What is Travere Therapeutics's email format?

Minus sign iconPlus sign icon
Travere Therapeutics's email format typically follows the pattern of First.Last@travere.com. Find more Travere Therapeutics email formats with LeadIQ.

How much funding has Travere Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, Travere Therapeutics has raised $1.5B in funding. The last funding round occurred on May 06, 2026 for $125M.

When was Travere Therapeutics founded?

Minus sign iconPlus sign icon
Travere Therapeutics was founded in 2020.
Travere Therapeutics logo

Travere Therapeutics

Biotechnology ResearchCalifornia, United States501-1000 Employees

Travere Therapeutics is a biotechnology research company based in San Diego that focuses on identifying, developing and delivering therapies for people with rare diseases. It operates in the biotechnology industry, has 501 to 1000 employees, and is headquartered at 3611 Valley Centre Drive Suite 300, San Diego, CA 92130, United States; more information is available on its website travere.com. In 2026, Travere executed a strategic asset acquisition from Everest Medicines, adding the civorebrutinib BTKi asset to its portfolio. The company announced leadership changes in 2026, appointing Inrig as executive vice president, head of research and development and chief medical officer, and stating that chief research officer William Rote plans to retire in 2027. Travere has a history of collaboration, notably a long-standing partnership with the Warren Center for Neuroscience Drug Discovery since 2015 to pursue treatments for NGLY1 deficiency.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
TVTX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2020
Employees
501-1000

Section iconFunding & Financials

  • $1.5B

    Travere Therapeutics has raised a total of $1.5B of funding over 9 rounds. Their latest funding round was raised on May 06, 2026 in the amount of $125M as a Post IPO Equity.

  • $250M - $500M

    Travere Therapeutics's revenue is estimated to be in the range of $250M - $500M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.